Skip to main content

Advertisement

SpringerLink
Log in

PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy.

Methods

Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled. The status of PSF1 expression was evaluated by immunohistochemistry, and the relationship between expression of PSF1 and Ki-67 was determined, as well as correlations between PSF1 expression and prognosis.

Results

We found that 27 of 69 patients’ tumors (39 %) were positive for PSF1 expression. The Ki-67 index was significantly higher in the PSF1-positive versus the PSF1-negative group (p = 0.0026). Five-year, disease-free survival of the PSF1-positive group was significantly worse (17.7 vs. 44.3 %, p = 0.0088), and the 5-year overall survival also was worse (16.6 vs. 47.2 %, p = 0.0059). Moreover, PSF1 expression was found to be a significant independent prognostic factor for shorter survival by Cox multivariate analysis (hazard ratio 2.43, 95 % confidence interval 1.27–4.60, p = 0.0076).

Conclusions

PSF1 is a useful prognostic biomarker to stratify NSCLC patients treated with surgery following preoperative chemotherapy or chemoradiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29.

    Article  Google Scholar 

  2. NCSLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.

    Article  Google Scholar 

  3. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999–5006.

    Article  CAS  PubMed  Google Scholar 

  4. Japan Lung Cancer Society. The clinical guide line for lung cancer, 3rd ed. Tokyo: Kanehara; 2014.

    Google Scholar 

  5. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.

    Article  CAS  PubMed  Google Scholar 

  6. Rosell R, Gomezcodina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung-cancer. N Engl J Med. 1994;330:153–8.

    Article  CAS  PubMed  Google Scholar 

  7. Toyooka S, Kiura K, Takemoto M, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yokomise H, Gotoh M, Okamoto T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–85.

    Article  CAS  PubMed  Google Scholar 

  9. Inoue M, Okumura M, Minami M, et al. Cardiopulmonary co-morbidity: a critical negative prognostic predictor for pulmonary resection following preoperative chemotherapy and/or radiation therapy in lung cancer patients. Gen Thorac Cardiovasc Surg. 2007;55:315–321.

    Article  PubMed  Google Scholar 

  10. Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Ohta M. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18:530–5.

    Article  PubMed  Google Scholar 

  11. Takayama Y, Kamimura Y, Okawa M, Muramatsu S, Sugino A, Araki H. GINS, a novel multiprotein complex required for chromosomal DNA replication in budding yeast. Genes Dev. 2003;17:1153–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bauerschmidt C, Pollok S, Kremmer E, Nasheuer HP, Grosse F. Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex, and DNA polymerases delta and epsilon during S phase. Genes Cells. 2007;12:745–58.

    CAS  PubMed  Google Scholar 

  13. Gambus A, Jones RC, Sanchez-Diaz A, Kanemaki K, van Deursen F, Edmondson RD, Labib K. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat Cell Biol. 2006;8:358–66.

    Article  CAS  PubMed  Google Scholar 

  14. Kanemaki M, Sanchez-Diaz A, Gambus A, Labib K. Functional proteomic identification of DNA replication proteins by induced proteolysis in vivo. Nature. 2003;423:720–4.

    Article  CAS  PubMed  Google Scholar 

  15. Moyer SE, Lewis PW, Botchan MR. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci. 2006;103:10236–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pacek M, Tutter AV, Kubota Y, Takisawa H, Walter JC. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication. Mol Cell. 2006;21:581–7.

    Article  CAS  PubMed  Google Scholar 

  17. Ueno M, Itoh M, Kong L, Sugihara K, Asano M, Takakura N. PSF1 is essential for early embryogenesis in mice. Mol Cell Biol. 2005;25:10528–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ueno M, Itoh M, Sugihara K, Asano M, Takakura N. Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration. Blood. 2009;113:555–62.

    Article  CAS  PubMed  Google Scholar 

  19. Nagahama Y, Ueno M, Miyamoto S, et al. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010;70:1215–24.

    Article  CAS  PubMed  Google Scholar 

  20. Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 2014;32:145–56.

    Article  CAS  PubMed  Google Scholar 

  21. Matsui T, Kinugasa Y, Tahara H, Kanakura Y, Takakura N. Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells. Am J Pathol. 2013;182:1790–9.

    Article  CAS  PubMed  Google Scholar 

  22. Nakahara I, Miyamoto M, Shibata T, et al. Up-regulation of PSF1 promotes the growth of breast cancer cells. Genes Cells. 2010;15:1015–24.

    Article  CAS  PubMed  Google Scholar 

  23. Tahara H, Naito H, Kise K, et al. Evaluation of PSF1 as a prognostic biomarker for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:56–62.

    Article  CAS  PubMed  Google Scholar 

  24. Zhou L, Sun XJ, Liu C, et al. Overexpression of PSF1 is correlated with poor prognosis in hepatocellular carcinoma patients. Int J Biol Markers. 2015;30:e56–64.

    Article  PubMed  Google Scholar 

  25. Japanese Lung Cancer Society. The general rule for clinical and pathological record of lung cancer. 7th ed. Tokyo: Kanehara; 2010.

    Google Scholar 

  26. Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636–48.

    Article  PubMed  Google Scholar 

  27. Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.

    Article  PubMed  Google Scholar 

  28. Tamura M, Sawabata N, Kobayashi S, et al. Prognostic significance of p21 protein expression in patients with pulmonary squamous cell carcinoma following induction chemotherapy. Ann Thorac Cardiovasc Surg. 2007;13:9–14.

    PubMed  Google Scholar 

  29. Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79:1–7.

    Article  PubMed  Google Scholar 

  30. Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank Ms. K. Fukuhara, Ms. N. Fujkimoto, and Ms. R. Inoue for technical assistance. This work was supported by Grants-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science (24300330), or Grant-in Research Center Network for Realization of Regenerative Medicine of Japan Agency for Medical Research and Development (AMED). The authors declare that they have no competing financial interests.

Author information

Authors and Affiliations

  1. Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Japan

    Ryu Kanzaki MD, Hisamichi Naito MD, PhD, Kazuyoshi Kise MD, PhD, Kazuhiro Takara PhD, Daisuke Eino MD & Nobuyuki Takakura MD, PhD

  2. Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita, Japan

    Ryu Kanzaki MD, Masato Minami MD, PhD, Yasushi Shintani MD, PhD, Soichiro Funaki MD, PhD, Tomohiro Kawamura MD, PhD, Toru Kimura MD, PhD & Meinoshin Okumura MD, PhD

Authors
  1. Ryu Kanzaki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisamichi Naito MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuyoshi Kise MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhiro Takara PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Eino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masato Minami MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasushi Shintani MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soichiro Funaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomohiro Kawamura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toru Kimura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Meinoshin Okumura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nobuyuki Takakura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuyuki Takakura MD, PhD.

Ethics declarations

Disclosure

Corresponding author belongs to GeneStem Co., Ltd., which produces anti-PSF1 antibody on a commercial basis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanzaki, R., Naito, H., Kise, K. et al. PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy. Ann Surg Oncol 23, 4093–4100 (2016). https://doi.org/10.1245/s10434-016-5392-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5392-z

Keywords

Search

Navigation